Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
Hair loss can occur while taking Mounjaro (tirzepatide), though it is not listed as a common direct side effect; it is most often linked to telogen effluvium, a temporary shedding triggered by rapid weight loss, reduced calorie and protein intake, and nutrient shortfalls such as iron, zinc, biotin, or vitamin D. Shedding typically starts two to four months after the trigger and usually resolves on its own within six to nine months once weight stabilizes and nutrition improves, meaning hair generally does grow back. Slowing weight loss, eating adequate protein, correcting deficiencies, and ruling out thyroid problems, hormonal shifts, or other conditions can all influence recovery. There are several important factors and warning signs to consider, including patchy loss, scalp irritation, or shedding that lasts beyond a year, so see below to understand more before assuming it is temporary.
Because hair changes can signal anything from a passing nutritional dip to an underlying thyroid or autoimmune issue, it is worth taking a few minutes to check your specific pattern of symptoms rather than waiting and hoping; a free, instant, online symptom check can help you understand the most likely explanations for what you are experiencing and guide you on whether to adjust your plan, request lab work, or speak with your prescriber next.
Last reviewed for medical accuracy: 09/26/2026
Can Mounjaro Cause Hair Loss? And If So, Does It Grow Back?
Mounjaro (tirzepatide) is a once-weekly injectable medication approved by the FDA for the treatment of type 2 diabetes and, more recently, for weight management. As with any medication, patients and clinicians want to know about possible side effects. One question that has surfaced in online forums and patient communities is: does Mounjaro cause hair loss? Below, we’ll review the available evidence, explore why hair shedding might occur, and discuss what you can do if you notice thinning hair.
• The FDA-approved prescribing information for Mounjaro lists the most common side effects, including:
• Hair loss (alopecia) is not included among the common or post-marketing side effects in the official label.
• Large, phase 3 clinical trials (SURPASS studies) involving thousands of patients did not report alopecia at rates higher than placebo.
Bottom line: There is no strong, direct clinical trial evidence that Mounjaro itself causes hair loss.
Despite the lack of clinical data, some patients have shared personal experiences of increased hair shedding after starting Mounjaro. It’s important to consider:
• Many variables change when patients begin tirzepatide:
• Stress on the body—whether from significant weight change or plateauing diets—can trigger a temporary shedding pattern called telogen effluvium.
Key point: Anecdotal reports don’t prove cause and effect. They point to an association that merits investigation.
Telogen effluvium is a common, reversible form of hair loss that can be triggered by various stressors. In the context of Mounjaro, potential triggers include:
Most cases of telogen effluvium begin two to four months after the trigger event and resolve within six to nine months once the body adjusts.
To determine whether Mounjaro itself is causing hair loss, you and your healthcare provider can:
If the hair loss began before Mounjaro, or if another culprit is found, it’s less likely that tirzepatide is the direct cause.
Don’t panic. Temporary shedding is common with metabolic and dietary changes.
Track your symptoms. Note when shedding began, diet changes, stress levels, and other new medications.
Optimize nutrition. Ensure you’re getting adequate:
Manage stress. Gentle exercise, adequate sleep, and relaxation techniques can help balance hormones.
Speak to a doctor if shedding is severe, sudden, or accompanied by other concerning symptoms.
You can also perform a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance.
In most cases of telogen effluvium, hair regrowth occurs naturally once the underlying cause is addressed. Here’s what you can expect:
• Timeline: Regrowth often starts 3–6 months after peak shedding, with full recovery by 9–12 months.
• New hair quality: Initial regrowth may appear finer or lighter; it usually normalizes over time.
• Supportive measures: Topical minoxidil (Rogaine) or low-level laser therapy may help in stubborn cases, as advised by a dermatologist.
If hair doesn’t begin to regrow after six months, or if the loss becomes patchy or scarring, see a dermatologist for further evaluation.
While temporary hair shedding can be benign, certain warning signs require prompt medical attention:
• Sudden, widespread bald patches
• Itching, redness, or pain on the scalp
• Signs of infection (fever, swelling)
• Hair loss associated with weight gain, fatigue, or other systemic symptoms
Always speak to a doctor if you experience any life-threatening or serious symptoms.
For many patients, Mounjaro offers substantial benefits in controlling blood sugar and achieving weight loss—factors that improve cardiovascular health, mobility, and overall quality of life. Weighing these benefits against a possible, but unproven, risk of hair shedding is a personal decision best made with your healthcare team.
By understanding the likely reasons behind hair shedding and working closely with your healthcare team, you can continue to reap the benefits of Mounjaro while minimizing and managing any unwanted changes in hair health.
(References)
* Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e153-e154. doi: 10.1111/jdv.20197. Epub 2024 Jun 24. PMID: 38925559.
* Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025 May;92(5):1141-1143. doi: 10.1016/j.jaad.2025.01.046. Epub 2025 Jan 23. PMID: 39863171.
* Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, Stegura C, Wine Lee L. A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies. J Drugs Dermatol. 2025 Apr 1;24(4):413-415. doi: 10.36849/JDD.8605. PMID: 40196945.
* Rojas Lopez RF, Lynett Barrera D, Amaya Muñoz MC, Saavedra Diaz MP. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus. 2025 Aug;17(8):e90021. doi: 10.7759/cureus.90021. Epub 2025 Aug 13. PMID: 40951222; PMCID: PMC12431796.
* Camino-Salvador JM, Rodríguez-Cuadrado FJ, Pinto-Pulido EL, Fernández-Parrado M. Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern. J Eur Acad Dermatol Venereol. 2026 May;40(5):e321-e323. doi: 10.1111/jdv.70088. Epub 2025 Sep 30. PMID: 41025593.
* Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, Zamandar A, Alkhames S. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025 Sep;17(9):e92454. doi: 10.7759/cureus.92454. Epub 2025 Sep 16. PMID: 41111833; PMCID: PMC12530271.
* Branyiczky MK, Lowe MS, McMullen E, Donovan J, Khosravi-Hafshejani T. Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review. Int J Dermatol. 2026 May;65(5):1030-1032. doi: 10.1111/ijd.70133. Epub 2025 Oct 31. PMID: 41174840; PMCID: PMC13067326.
* Herrera HO, Bordeaux JS. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. J Am Acad Dermatol. 2026 Jun;94(6):1826-1827. doi: 10.1016/j.jaad.2026.02.042. Epub 2026 Feb 17. PMID: 41707704.
* Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026 Apr-Jun;109(2):368504261444578. doi: 10.1177/00368504261444578. Epub 2026 Apr 17. PMID: 41998799; PMCID: PMC13100445.
* Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2026 Jul;237:113333. doi: 10.1016/j.diabres.2026.113333. Epub 2026 May 18. PMID: 42155605.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.